FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1987162625> ?p ?o ?g. }

• W1987162625 endingPage "296" @default.
• W1987162625 startingPage "291" @default.
• W1987162625 abstract "Cisplatin (C) or carboplatin (CBP) plus cyclophosphamide (CTX) was until recently considered standard chemotherapy for advanced ovarian cancer (OC). Attempts to maximize platinum and its analog activity against OC include its administration directly into the peritoneal cavity. In the past we have shown that intraperitoneal (IP) CBP administration is a safe and effective treatment for OC [Polyzos et al: Proc Am Assoc Cancer Res 1990;31: 1120]. In the present study we aimed to compare the effectiveness and toxicity of CBP administration either intravenously (IV) or IP plus CTX IV. Since 1990, 90 evaluable patients with stage III OC were prospectively randomized to receive CBP 350 mg/m² IV or IP plus CTX 600 mg/m² IV (in both groups) every 3–4 weeks for six courses. The randomization incorporated stratification according to performance status and the amount of residual tumor (maximum diameter ≤2 or >2 cm). Clinical assessment was performed with abdominal CT and serum CA-125. Responses were observed in 33/46 = 72% (95/CI 56.5–84.0) of the IV group and in 33/44 = 75% (95/CI 59.7–86.8) of the IP group with 48 and 45% clinical complete responses, respectively. Times to progression were 19 months (8–62+) for the IV group and 18 (6–72+) for the IP group. Median survivals were: 25 months (6–80+) and 26 months (6–72+), respectively. Significantly more patients in the IV group than in the IP group had grade 3 or higher leukopenia (p < 0.01) and grade 3 thrombocytopenia (p < 0.09). Morbidity due to infectious complications in the IP group was minimal. It seems that IP CBP is equally effective to IV administration in terms of response and survival with less myelotoxicity. The favorable results on survival demonstrated in studies with IP C administration in patients with small volume disease [Alberts et al: N Engl J Med 1996;335:1950–1965] could not be repeated in the present study applying CBP in patients with variable tumor size and a relatively small number of patients. The likelihood that patients with large volume disease would benefit from a regional approach compared to systemic administration is small and this explains the inability to detect a difference between the two arms." @default.
• W1987162625 created "2016-06-24" @default.
• W1987162625 creator A5000300045 @default.
• W1987162625 creator A5001577925 @default.
• W1987162625 creator A5004885516 @default.
• W1987162625 creator A5009593791 @default.
• W1987162625 creator A5014735902 @default.
• W1987162625 creator A5042604073 @default.
• W1987162625 creator A5051679707 @default.
• W1987162625 creator A5072956257 @default.
• W1987162625 creator A5074407673 @default.
• W1987162625 creator A5086606757 @default.
• W1987162625 creator A5089910357 @default.
• W1987162625 date "1999-01-01" @default.
• W1987162625 modified "2023-10-18" @default.
• W1987162625 title "A Comparative Study of Intraperitoneal Carboplatin versus Intravenous Carboplatin with Intravenous Cyclophosphamide in Both Arms as Initial Chemotherapy for Stage III Ovarian Cancer" @default.
• W1987162625 cites W2014114494 @default.
• W1987162625 cites W2316501478 @default.
• W1987162625 doi "https://doi.org/10.1159/000011980" @default.
• W1987162625 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10343192" @default.
• W1987162625 hasPublicationYear "1999" @default.
• W1987162625 type Work @default.
• W1987162625 sameAs 1987162625 @default.
• W1987162625 citedByCount "101" @default.
• W1987162625 countsByYear W19871626252012 @default.
• W1987162625 countsByYear W19871626252014 @default.
• W1987162625 countsByYear W19871626252015 @default.
• W1987162625 countsByYear W19871626252016 @default.
• W1987162625 countsByYear W19871626252017 @default.
• W1987162625 countsByYear W19871626252018 @default.
• W1987162625 countsByYear W19871626252019 @default.
• W1987162625 countsByYear W19871626252021 @default.
• W1987162625 countsByYear W19871626252022 @default.
• W1987162625 countsByYear W19871626252023 @default.
• W1987162625 crossrefType "journal-article" @default.
• W1987162625 hasAuthorship W1987162625A5000300045 @default.
• W1987162625 hasAuthorship W1987162625A5001577925 @default.
• W1987162625 hasAuthorship W1987162625A5004885516 @default.
• W1987162625 hasAuthorship W1987162625A5009593791 @default.
• W1987162625 hasAuthorship W1987162625A5014735902 @default.
• W1987162625 hasAuthorship W1987162625A5042604073 @default.
• W1987162625 hasAuthorship W1987162625A5051679707 @default.
• W1987162625 hasAuthorship W1987162625A5072956257 @default.
• W1987162625 hasAuthorship W1987162625A5074407673 @default.
• W1987162625 hasAuthorship W1987162625A5086606757 @default.
• W1987162625 hasAuthorship W1987162625A5089910357 @default.
• W1987162625 hasConcept C121608353 @default.
• W1987162625 hasConcept C126322002 @default.
• W1987162625 hasConcept C126894567 @default.
• W1987162625 hasConcept C141071460 @default.
• W1987162625 hasConcept C146357865 @default.
• W1987162625 hasConcept C151730666 @default.
• W1987162625 hasConcept C168563851 @default.
• W1987162625 hasConcept C204243189 @default.
• W1987162625 hasConcept C2776694085 @default.
• W1987162625 hasConcept C2776755627 @default.
• W1987162625 hasConcept C2778239845 @default.
• W1987162625 hasConcept C2780427987 @default.
• W1987162625 hasConcept C2781451048 @default.
• W1987162625 hasConcept C71924100 @default.
• W1987162625 hasConcept C86803240 @default.
• W1987162625 hasConcept C90924648 @default.
• W1987162625 hasConceptScore W1987162625C121608353 @default.
• W1987162625 hasConceptScore W1987162625C126322002 @default.
• W1987162625 hasConceptScore W1987162625C126894567 @default.
• W1987162625 hasConceptScore W1987162625C141071460 @default.
• W1987162625 hasConceptScore W1987162625C146357865 @default.
• W1987162625 hasConceptScore W1987162625C151730666 @default.
• W1987162625 hasConceptScore W1987162625C168563851 @default.
• W1987162625 hasConceptScore W1987162625C204243189 @default.
• W1987162625 hasConceptScore W1987162625C2776694085 @default.
• W1987162625 hasConceptScore W1987162625C2776755627 @default.
• W1987162625 hasConceptScore W1987162625C2778239845 @default.
• W1987162625 hasConceptScore W1987162625C2780427987 @default.
• W1987162625 hasConceptScore W1987162625C2781451048 @default.
• W1987162625 hasConceptScore W1987162625C71924100 @default.
• W1987162625 hasConceptScore W1987162625C86803240 @default.
• W1987162625 hasConceptScore W1987162625C90924648 @default.
• W1987162625 hasIssue "4" @default.
• W1987162625 hasLocation W19871626251 @default.
• W1987162625 hasLocation W19871626252 @default.
• W1987162625 hasOpenAccess W1987162625 @default.
• W1987162625 hasPrimaryLocation W19871626251 @default.
• W1987162625 hasRelatedWork W196860179 @default.
• W1987162625 hasRelatedWork W1984775533 @default.
• W1987162625 hasRelatedWork W2080529225 @default.
• W1987162625 hasRelatedWork W2082620515 @default.
• W1987162625 hasRelatedWork W2085363994 @default.
• W1987162625 hasRelatedWork W2154765149 @default.
• W1987162625 hasRelatedWork W2280856801 @default.
• W1987162625 hasRelatedWork W2419075599 @default.
• W1987162625 hasRelatedWork W2463572748 @default.
• W1987162625 hasRelatedWork W5763337 @default.
• W1987162625 hasVolume "56" @default.
• W1987162625 isParatext "false" @default.
• W1987162625 isRetracted "false" @default.
• W1987162625 magId "1987162625" @default.
• W1987162625 workType "article" @default.